Q&A: Using liquid biopsies 
to build CDx in pancreatic cancer with Actuate Therapeutics

Dr. Andrew Mazar of Actuate Therapeutics shares his perspective on liquid biopsy as a tool for CDx and drug development in pancreatic cancer.

Jun 28, 2023
Life Sciences
Article
Michael YasiejkoGeneral Manager and Executive Vice President, Tempus
Andrew Mazar, PhDChief Operating Officer, Actuate

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Person works on computer with abstract digital code and data patterns overlayed.

Bridging the gap: How Target Trial Emulation transforms real-world data into credible evidence

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract digital background with glowing white lines and a fading dotted pattern.

Q&A: Predicting response and resistance in ADCs with AI and multimodal data

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract background with light grey gradient, digital dots, and subtle wave patterns.

Researchers across pharma and academia are reducing oncology drug timelines with Tempus Lens

2026-08-12
Life Sciences